Vaccination is one of the cleanest ways researchers can study human immune variation. The antigenic challenge is more standardized than a natural infection, yet the immune response still differs substantially from person to person.
Twin studies make that variation especially informative. They show that inherited biology can contribute to specific antibody-response traits, but they also show why one heritability estimate cannot be turned into a personal percentage or a universal rule about vaccine protection.
Quick answer
If two people receive the same vaccine, should they produce essentially the same immune response?
No. Twin and genetic studies show that inherited differences can contribute to some measured vaccine responses, while age, prior immunity, baseline immune state, health context, metabolism, microbiome and other influences also matter. The size and meaning of those contributions depend on the vaccine and the immune endpoint being measured.
Key takeaways
- In a 2002 study of 202 twin pairs receiving combined hepatitis A/B vaccination, the measured anti-HBs antibody response showed a stronger inherited component than the anti-HAV response.
- A Gambian Hib-vaccine study in 43 MZ and 147 DZ twin pairs also found a substantial inherited contribution to the measured antibody response.
- These heritability estimates describe population variation in specific studies; they are not personal genetic percentages and cannot be generalized to every vaccine.
- A 2025 human vaccine-genetics review describes vaccine response as the product of interacting heritable and environmental factors, including important HLA effects.
- A 2026 Nature review of systems vaccinology emphasizes host genetics, metabolism, microbiome and baseline immune state while also warning that translation into routine clinical prediction remains difficult.
- Antibody response is one component of immunity. A lower measured antibody response does not automatically mean a person has no protection.
Vaccines create a useful scientific test of immune variation
Natural infections are messy exposures. People encounter different doses, variants, routes and timing. Vaccination gives researchers a more standardized immune challenge, making it easier to ask why responses still differ between individuals.
That does not make vaccine response a single number. Researchers can measure antibody concentration, neutralization, memory cells, T-cell responses, durability and other outcomes. Different endpoints can have different determinants.
The hepatitis A/B twin study found different genetic signals for different responses
Höhler and colleagues prospectively vaccinated 202 twin pairs with a combined hepatitis A and B vaccine and measured antibody responses to both antigens. The fitted heritability estimate was 0.61 for anti-HBs and 0.36 for anti-HAV, with much wider uncertainty around the hepatitis A estimate.
The contrast matters. Even within the same vaccinated twin cohort, the estimated inherited contribution depended on which immune response was measured. That is the opposite of a universal “vaccine response is X% genetic” rule.
HLA mattered — but it was not the whole explanation
For the hepatitis B surface-antigen response, the investigators estimated that HLA-DRB1 explained part of the inherited variation, while additional genetic effects lay outside that locus.
This fits modern immunogenetics: antigen presentation through HLA can shape immune responses, but no single HLA result should be treated as a personal protection score or as a deterministic explanation of vaccine effectiveness.
A Gambian twin study found another vaccine-specific inherited component
A 2006 study measured antibody responses to Hib conjugate vaccination in 43 monozygotic and 147 dizygotic twin pairs in The Gambia. The estimated heritability of the measured anti-PRP antibody response was 51%, with a 95% confidence interval of 32–66%.
Again, this is a population variance estimate for one vaccine, one antibody endpoint and one study population. It cannot be transferred directly to influenza, COVID-19, hepatitis, MMR or another vaccine.
Modern vaccine genetics has moved far beyond one twin estimate
A 2025 review of human vaccine genetics describes substantial variability in vaccine responses arising from a combination of heritable and environmental factors. Research from the COVID-19 era expanded the scale of human genetic studies and highlighted associations across HLA and other immune pathways.
The useful conclusion is not that genetics “controls” vaccination. It is that inherited biology is one layer in a multi-layer response, and that the relevant layer can change with vaccine platform, antigen, age and outcome.
Systems vaccinology explains why the starting state matters
A 2026 Nature review describes vaccination as a controlled probe of human immunity and highlights how host genetics, metabolism and the microbiome help shape immune responses alongside baseline immune state and early response dynamics.
That framework makes variation expected rather than surprising. Two people can receive the same vaccine but begin with different immune histories, metabolic states, microbial ecosystems and cellular programs.
Antibodies are important — but they are not the whole immune response
The classic twin studies above focused on measured antibody responses. Antibodies can be valuable correlates of immunogenicity and, for some vaccines, protection. But protection can also involve antibody quality, memory B cells, T cells, mucosal immunity and other mechanisms.
A lower antibody concentration at one time point therefore should not be rewritten as “the vaccine did not work”. The biological and clinical meaning depends on the vaccine, assay, timing and established correlates of protection.
What identical twins can — and cannot — show
If genetically identical twins respond differently to the same vaccination, shared DNA was not sufficient to make their measured responses identical. That is scientifically useful because it shows room for nonshared influences and biological history.
But discordance does not identify the cause. It does not prove that diet, stress, sleep, microbiome or another specific exposure created the difference unless those mechanisms are tested directly.
Funding and competing interests still matter
The 2026 systems-vaccinology review used here acknowledges support from the NIH, the Bill & Melinda Gates Foundation, Open Philanthropy, DARPA and other donors. Its author also reports current or past advisory roles involving several vaccine and pharmaceutical companies and shareholdings in two companies.
Those disclosures do not invalidate the review, but they are relevant context and should remain visible when a modern synthesis is used prominently in health reporting.
TwinPare boundary
TwinPare Research can explain why vaccine-induced immune responses vary and how twin studies separate some inherited from nonshared variation. It does not tell a reader whether they are personally protected or whether they should receive, skip or reschedule a vaccine.
TwinPare Health & Fitness does not measure vaccine effectiveness, antibody protection, immune deficiency or personal vaccine response from wearables or ordinary app data. Individual vaccination questions belong with qualified healthcare or public-health guidance.
Source notes
The sources have been verified and editorially reviewed for this article. The limitations below show which level of conclusion the sources support.
- [hoehler-hepatitis-ab-vaccine-twins-2002] Differential genetic determination of immune responsiveness to hepatitis B surface antigen and to hepatitis A virus: a vaccination study in twins Thomas Höhler et al.. The Lancet, 2002. Evidence type: Open prospective combined hepatitis A/B vaccination study in 202 twin pairs Limitation: Anti-HBs response heritability was estimated at 0.61 (95% CI 0.41–0.81), while anti-HAV was 0.36 with wide uncertainty. These are population variance estimates for specific measured antibody responses, not personal genetic percentages or universal vaccine-response values. PubMed DOI
- [lee-hib-vaccine-gambian-twins-2006] Influence of genetic and environmental factors on the immunogenicity of Hib vaccine in Gambian twins Y C Lee et al.; MRC Twin Study Group. Vaccine, 2006. Evidence type: Hib conjugate vaccine antibody-response study in 43 MZ and 147 DZ Gambian twin pairs Limitation: Heritability of the measured anti-PRP antibody response was estimated at 51% (95% CI 32–66%). The estimate is vaccine-, endpoint-, population- and study-specific and must not be generalized to all vaccines or individuals. PubMed DOI
- [karp-tatham-human-vaccine-genetics-2025] Human genetics of responses to vaccines Eleanor Karp-Tatham; Julian C Knight; Alexandre Bolze. Clinical and Experimental Immunology, 2025. Evidence type: Review of human genetic influences on vaccine immunogenicity, efficacy and rare adverse events Limitation: The review emphasizes substantial response variability from interacting heritable and environmental factors and highlights modern HLA associations. The authors declared no conflicts of interest. PubMed PMC DOI
- [pulendran-systems-vaccinology-2026] Systems vaccinology and the architecture of human immunity Bali Pulendran. Nature, 2026. Evidence type: 2026 systems-vaccinology review using vaccination as a controlled probe of human immune variation Limitation: The review describes roles for host genetics, metabolism, microbiome, baseline immune state and early response dynamics, while emphasizing translation limits. Funding included NIH, Bill & Melinda Gates Foundation, Open Philanthropy, DARPA and other donors. The author reported current or past roles involving GSK, Pfizer Vaccines, Sanofi, Medicago, Boehringer Ingelheim, Pharmajet, Icosavax, Imu Biosciences and Ed-Jen, plus shareholdings in CircBio and Orbital Therapeutics; those disclosures remain visible here. PubMed DOI
Editorial source review
This section shows how the article's key factual claims are linked to the source.
Phrasings that require caution
- Do not write that a person’s vaccine response is 61%, 51% or any other fixed percentage genetic.
- Do not generalize one vaccine, antigen, age group or population to all vaccines.
- Do not equate antibody concentration with complete immune protection.
- Do not say a lower measured antibody response means that a vaccine failed for an individual.
- Do not imply identical-twin discordance identifies the environmental cause.
- Do not provide individualized vaccination schedules or recommendations.
- Do not imply TwinPare or wearable data measures vaccine effectiveness, immune protection or immune deficiency.
- Keep the 2026 systems-vaccinology funding and competing-interest disclosures visible.
| ID | Claim | Source support | Caution |
|---|